Imbed Biosciences Inc., a Madison company with a novel biomaterials platform for wound dressings and surgical implants, has raised $683,000 of a planned $1 million funding round, according to filings with federal securities regulators.
Cellular Dynamics International Inc. said Thursday it has been granted a U.S. patent on the automated production of cells that can be grown into any of the more than 200 types of cells in the body.
The Morgridge Institute Medical Engineering team, responding to increased UW-Madison demand for microfluidics resources, has launched a new microfluidics foundry to build customized tools that bring biology down to the smallest possible scale.
Exact Sciences Corp. announced that Mayo Clinic will be the first health system to offer Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer.
Silatronix, a Madison-based startup working to make lithium ion batteries safer and more efficient, has secured $2.8 million in venture funding.
Following the recent FDA approval of Exact Sciences’ Cologuard® product, the first non-invasive, DNA screening test for colorectal cancer, the company must convince healthcare providers and consumers of the effectiveness of the product.
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test.
Imbed Biosciences, Inc. announced today that it has been awarded a $1.5M competitive Small Business Innovation Research (SBIR) Phase II grant from National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of National Institutes of Health (NIH).
Exact Sciences Corp. today announced that James E. Doyle and Maneesh K. Arora were elected to company’s board of directors at its annual meeting of stockholders. Lionel N. Sterling has served as a director of Exact since 2010 and was reelected to the board.
The Board of Trustees of the Morgridge Institute for Research has approved a new Morgridge focus area in metabolism, a growing research field with enormous potential to treat or reverse a broad spectrum of human diseases.